Liesbeth van de Ven

Liesbeth Van de Ven is a skilled Senior Medical Writer at argenx since January 2023, previously serving as a Medical Writer at Emtex Life Science from March 2020 to January 2023, and as a Senior Research Associate at argenx from November 2015 to February 2020, where preclinical development of ARGX-117 was conducted. Liesbeth also has experience as a Research Associate focused on monoclonal antibody isolation and optimization at argenx and in isolating and screening Nanobodies® at Ablynx from September 2013 to October 2015. Earlier experiences include a student internship at ProDigest evaluating fermentability of wheat-derived arabinoxylans and another at the University of California at San Diego examining calmodulin binding proteins from Giardia lamblia. Liesbeth holds a Master of Science degree in Biochemistry and Biotechnology from Ghent University and a Bachelor's degree in Biomedical Technology/Technician from HOGENT.